Satyanarayana Chava – CEO, Laurus Labs, India
Dr. Satyanarayana Chava, founder and CEO of Laurus Labs, provides insights into the distinctive model that has allowed Laurus to become one of the world’s leading API companies as well…
Laurus Labs Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (APIs) in India and internationally. It operates through Laurus Generics APIs, Laurus Generics Finished Dosage Forms (FDF), Laurus Synthesis, and Laurus Ingredients divisions.
The Laurus Generics APIs division develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), Hepatitis C, cardiovascular, antidiabetic, anti-asthmatic, gastroenterology, oncology, and ophthalmic therapeutic areas. The Laurus Generics Finished Dosage Forms division develops and manufactures oral solid formulations, such as ARVs, anti-diabetic, cardiovascular, and proton pump inhibitors.
The Laurus Synthesis division provides contract development and manufacturing services for pharmaceutical companies. The Laurus Ingredients division manufactures and sells speciality ingredients for use in the nutraceutical/dietary supplements and cosmeceutical products. In addition, it offers chemistry, IP development, business support, and related services to the pharmaceutical community. The company was incorporated in 2005 and is based in Hyderabad, India. Laurus Labs Limited is a subsidiary of Aptuit LLC.
Dr. Satyanarayana Chava, founder and CEO of Laurus Labs, provides insights into the distinctive model that has allowed Laurus to become one of the world’s leading API companies as well…
If we look back at the conditions under which you founded Biocon in 1978, we see a young woman with a seed capital of only Rs. 10,000 in a garage…
You have already publicly announced that, despite being late in India, Lonza has been increasingly looking into expanding in the Indian market. First of all, what do you think sparked…
Before moving into the company’s strategy, can you give our readers an idea of what role Boehringer Ingelheim India plays within the Group’s worldwide operations? Within the Boehringer Ingelheim Group,…
To start off, can you tell us how you have seen the pharmaceutical industry developing in India? Has the perception of India by big pharma changed over the years? First…
A catalyst of India’s shifting industry dynamics has been the sector’s M&A activity. We already saw majors such as Piramal going to Abbott and Ranbaxy to Daiichi-Sankyo… And while Andrew…
With the recent event “Vibrant Gujarat”, the state of Gujarat aimed to showcase the region’s opportunities and advanced infrastructure, hosting 1,400 delegates from 101 countries as well as several presentations…
You founded Calyx in 1979 with a three-person team. At the time, you were just 21 years old! What was the vision behind the creation of the company? Essentially, the…
You joined Wockhardt in 2000; you became a member of the board in 2006, and were appointed managing director in 2009. The Indian industry has undergone many changes in the…
Glenmark may be poised to release India’s first novel drug, from the in-licensed, anti-diarrheal molecule Crofelemer. Crofelemer has successfully complete Phase III trials, and you are readying to release it…
Since we last met in 2006, the Indian pharmaceutical industry has been doing very well indeed, as a very large number of drugs came off patent. This trend will continue…
Since we last met in 2006, the Indian pharmaceutical industry has been doing very well indeed, as a very large number of drugs came off patent. This trend will continue…
Our last report on India dates back to 2006, right after the Patent Law was passed. What developments have you seen happening in the industry since then? There has been…
See our Cookie Privacy Policy Here
